---
title: "Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295837729.md"
description: "JonesTrading analyst Debanjana Chatterjee initiated coverage of Trevi Therapeutics with a Buy rating and $28 price target, citing clean late-stage execution, de-risked IPF cough and RCC pipelines, and a solid cash position. Key milestones include OCEAN-1 data in 1H28 and accelerated Phase 3 trials. H.C. Wainwright also maintains a Buy rating with a $24 target."
datetime: "2026-08-13T19:35:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295837729.md)
  - [en](https://longbridge.com/en/news/295837729.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295837729.md)
generator: "portal-rs"
---

# Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position

In a report released today, Debanjana Chatterjee from JonesTrading maintained a Buy rating on Trevi Therapeutics, with a price target of $28.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Debanjana Chatterjee has given his Buy rating due to a combination of factors including Trevi Therapeutics’ clean late-stage execution and strong financial position to advance its cough portfolio. The company is progressing its pivotal IPF-related chronic cough study OCEAN-1 with data expected in 1H28, while a second Phase 3 IPF trial is being accelerated into 3Q26, underscoring management’s ability to tighten timelines and de-risk clinical milestones.

At the same time, Trevi’s Phase 2b RCC program is structured with an upcoming SSRE analysis that provides an option to resize the trial if needed, creating a disciplined path to robust data by 2H27. Chatterjee also sees strategic value in the company’s pricing and market access approach, as management aims to preserve premium IPF/ILD pricing while still capturing a significantly expanded RCC opportunity with targeted patient selection and the potential for a differentiated brand and dose strategy, all supported by a solid cash balance to fund these initiatives. 

Chatterjee covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, Opus Genetics, and AbCellera Biologics. According to TipRanks, Chatterjee has an average return of 45.6% and a 66.12% success rate on recommended stocks. 

In another report released on August 11, H.C. Wainwright also maintained a Buy rating on the stock with a $24.00 price target.

### Related Stocks

- [TRVI.US](https://longbridge.com/en/quote/TRVI.US.md)
- [EYPT.US](https://longbridge.com/en/quote/EYPT.US.md)
- [IRD.US](https://longbridge.com/en/quote/IRD.US.md)
- [ABCL.US](https://longbridge.com/en/quote/ABCL.US.md)

## Related News & Research

- [Sei Investments Co. Has $933,000 Holdings in Trevi Therapeutics, Inc. $TRVI](https://longbridge.com/en/news/295765971.md)
- [Trevi Therapeutics: Buy Rating Reiterated on Haduvio’s Cough Program Progress and Strong Cash Runway; $23 Price Target Unchanged](https://longbridge.com/en/news/295280894.md)
- [Nasdaq 100 Short Exposure Hits $20 Billion as Insiders Near ‘15-Year High’ in Buying: Is a Squeeze Imminent?](https://longbridge.com/en/news/296200499.md)
- [United Therapeutics seeks FDA priority review for Tyvaso label expansion in IPF](https://longbridge.com/en/news/296094667.md)
- [Since Mat Ishbia didn’t have to sell a ton of stock in …](https://longbridge.com/en/news/296385483.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**